Pancreatic Cancer Screening of High-Risk Individuals in Arkansas

University of Arkansas1 site in 1 countryNovember 2015

ConditionsColorectal Neoplasms, Hereditary Nonpolyposis Hereditary Pancreatitis Pancreatic Neoplasms Peutz-Jegher's Syndrome BRCA1 Gene Mutation BRCA2 Gene Mutation Ataxia Telangiectasia Familial Atypical Mole-Malignant Melanoma Syndrome

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Colorectal Neoplasms, Hereditary Nonpolyposis
Sponsor: University of Arkansas
Locations: 1
Primary Endpoint: Detection rate of PC and precancerous lesion
Status: Withdrawn
Last Updated: 6 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

100 subjects who have a family history of pancreatic cancer (PC), or known genetic syndromes associated with increased risk of pancreatic cancer, will be followed for five years. This data will be used to determine the pancreatic cancer and precancerous lesion detection rate in High Risk Individuals (HRIs). Subjects may agree to annual imaging and annual biomarkers or to biomarkers only.

Registry

clinicaltrials.gov

Start Date

November 2015

End Date

July 19, 2019

Last Updated

6 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

University of Arkansas

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Have a family history of PC as listed below or who have one of the following syndromes: Peutz-Jeghers syndrome - STK11; BRCA 1 and 2; PALB2; ATM; FAMMM / P16; HNPCC (Lynch) / MMR genes; Hereditary pancreatitis - PRSS1
•Individuals with three or more affected blood relatives (1st, 2nd or 3rd degree)
•Individuals with two or more affected blood relatives with PC, with at least one affected FDR, should be considered for screening.
•Patients with a history of Peutz-Jeghers syndrome should be screened, regardless of family history of PC.
•Patients with a known p16 (FAMMM syndrome) with one affected 1st or 2nd degree relative will be considered for screening.
•Patients with a known BRCA1 or BRCA2 mutation with one affected 1st or 2nd degree relative should be considered for screening.
•Patients with a known PALB2 mutation with one affected family member should be considered for screening.
•Patients with a known Mismatch-repair gene-mutation carriers (Lynch syndrome) with one affected family member should be considered for screening.